<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Date of Report (Date of earliest event reported): NOVEMBER 12, 1999
-----------------
QUIDEL CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Commission file number 0-10961
-------
DELAWARE 94-2573850
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
10165 MCKELLAR COURT, SAN DIEGO, CA 92121
(Address of Principal Executive Offices)
TELEPHONE (858) 552-1100
(Registrant's Telephone Number, Including Area Code)
<PAGE>
QUIDEL CORPORATION
FORM 8-K
CURRENT REPORT
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C> <C>
Item 5. Other Event 3
Signature 4
</TABLE>
<PAGE>
ITEM 5. OTHER EVENT
Quidel Corporation is filing this report on Form 8-K to report that it has
entered into a Letter of Intent with Dade Behring for the acquisition of the
assets of the Dade Behring Rapignost(R) Urine Test Strip business. The proposed
cash price is $5.75 million (including deferred payments) plus up to an
additional $3 million on an earn-out basis. The proposed transaction is subject
to a number of contingencies and the parties have targeted a closing date before
the end of the year. Included in the proposed transaction are continuing
manufacturing obligations and certain distribution rights of Dade Behring.
Quidel intends on paying for this acquisition by accessing its bank line of
credit.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
QUIDEL CORPORATION
Date: NOVEMBER 19,1999 /s/ CHARLES J. CASHION
---------------- ----------------------------------
Charles J. Cashion
Senior Vice President,
Corporate Operations,
Chief Financial Officer and
Secretary
